Shionogi secures USD 482 million BARDA Project BioShield contract for Fetroja

Shionogi's New Jersey subsidiary has [secured a contract](https://www.shionogi.com/us/en/news/2026/04/shionogi-receives-contract-with-us-government-through-bardas-project-bioshield-to-enhance-national-preparedness-for-drug-resistant-bacterial-threats.html) through BARDA's Project BioShield program worth an initial USD 119 million, with multiyear options bringing the total potential value to USD 482 million. The award centers on [cefiderocol](https://app.allsci.com/drugs/ASC-DR-0000000024334-1.0-1772718717), marketed as Fetroja, the company's siderophore cephalosporin antibiotic approved by the US FDA for hospital-acquired and ventilator-associated bacterial pneumonia and complicated urinary tract infections caused by susceptible Gram-negative organisms. The contract was awarded to Shionogi Inc., the New Jersey-based US subsidiary of Osaka-headquartered Shionogi & Co., Ltd., by the Biomedical Advanced Research and Development Authority under the Project BioShield framework, which funds medical countermeasures against chemical, biological, radiological, and nuclear threats. Funding flows from the US Department of Health and Human Services' Administration for Strategic Preparedness and Response under contract number 75A50126C00004. The agreement covers four distinct workstreams: establishing a US drug product manufacturing site for Fetroja; supporting procurement of the antibiotic; advancing cefiderocol as a treatment for infections caused by high-priority biothreat pathogens, specifically Burkholderia pseudomallei, the causative agent of melioidosis, and Yersinia pestis, the causative agent of plague; and pursuing a supplemental new drug application with the US FDA to extend Fetroja's approved indications to cover HABP/VABP in pediatric patients. Cefiderocol is described by the company as the first siderophore cephalosporin antibiotic. Its mechanism exploits bacterial iron-acquisition pathways: the drug's catechol moiety chelates extracellular ferric iron, and the resulting complex is actively transported across the bacterial outer membrane via TonB-dependent receptors — the same machinery bacteria rely on to scavenge iron from host tissues. Once inside the periplasm, cefiderocol inhibits penicillin-binding protein 3, disrupting cell wall synthesis. The approach bypasses porin channels, which Gram-negative organisms frequently downregulate as a resistance mechanism, and the molecule retains activity against all four Ambler classes of beta-lactamases, including the metallo-beta-lactamases and serine carbapenemases that defeat conventional carbapenems. Active clinical work with cefiderocol includes a [pharmacokinetic study in patients with acute burn injuries](https://app.allsci.com/clinical-trial/ASC-CT-0000001151751-1.0-1773325169) and an [expanded access program](https://app.allsci.com/clinical-trial/ASC-CT-0000000247652-1.0-1745779469) for severe Gram-negative infections. Beyond cefiderocol, Shionogi's pipeline spans antimicrobial resistance, influenza, COVID-19, rare fungal diseases, and respiratory syncytial virus, alongside a separate R&D focus on pain, CNS disorders including Alzheimer's disease, oncology, and sleep apnea. The company acquired Qpex Biopharma in 2023 and subsequently invested in a dedicated Qpex research facility in 2025. Through Qpex, the company said it is advancing a portfolio of clinical-stage antimicrobial compounds, including xeruborbactam (QPX7728) and its oral prodrug QPX7831, with active studies including a [pharmacokinetic and safety study of the oral prodrug combined with ceftibuten in participants with renal impairment](https://app.allsci.com/clinical-trial/ASC-CT-0000000027714-1.0-1745700230). Shionogi has maintained an active relationship with US government agencies in the antimicrobial space. The company previously received CARB-X grant funding in 2018 to develop an antibiotic targeting carbapenem-resistant Enterobacteriaceae, and separately secured BARDA support for its COVID-19 antiviral program. In early 2026, the company completed a USD 2.125 billion transaction to increase its economic interest in ViiV Healthcare, the GSK-led HIV joint venture, from 10% to 21.7% following Pfizer's exit from that partnership. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/barda-project-bioshield-contract-shionogi-secures)